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http://dxObjective: Acute renal injury after cardiopulmonary bypass is common and associated with high mortality. We
aimed to demonstrate the glomerular protective effects of recombinant human erythropoietin using an in vivo rat
cardiopulmonary bypass model and to explore the possible mechanism.
Methods: Dose-related renal protective effects of recombinant human erythropoietin were studied in phase I.
Male Sprague Dawley rats were randomly divided into 5 groups: sham group, cardiopulmonary bypass group,
and 3 recombinant human erythropoietin–treated cardiopulmonary bypass groups (bolus doses of 500, 3000, and
5000 U/kg 24 hours before surgery). Blood and urine samples were collected just before surgery and at 2, 4, 24,
48, and 72 hours after surgery. In phase II, rats were divided into 3 groups: sham group, cardiopulmonary bypass
group, and 5000 U/kg recombinant human erythropoietin group. Kidneys were harvested at 4, 24, 48, and 72
hours after surgery. Ultra-organization of glomeruli was observed. Glomerular transient receptor potential
channel 6 (TRPC6) expression was studied by immunofluorescence and Western blot. Nuclei nuclear factor
of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1) activity was analyzed by enzyme-linked
immunosorbent assays and electrophoretic mobility shift assay.
Results: Pretreatment of 5000 U/kg recombinant human erythropoietin decreased the urine protein (72 hours:
7.82 1.13 g/L vs 11.28 1.73 g/L), serum creatinine (72 hours: 35.0 3.5 mmol/L vs 60.7 7.6 mmol/L), and
cystatin-C (2 hours: 336.5  28.2 mg/L vs 452.6  63.8 mg/L) compared with the control group (P< .01).
Cardiopulmonary bypass induced morphologic abnormalities of podocyte foot processes and slit diaphragms,
which was improved by recombinant human erythropoietin. Furthermore, recombinant human erythropoietin
significantly relieved glomerular TRPC6 increase and NFATc1 activation induced by cardiopulmonary bypass.
Conclusions: Pretreatment of 5000 U/kg recombinant human erythropoietin elicited potent glomerular protec-
tion against cardiopulmonary bypass. This protection may be partly due to downregulation of glomerular
TRPC6-NFATc1 pathway. (J Thorac Cardiovasc Surg 2013;146:681-7)P
MAcute renal injury (ARI) occurs in up to 30% of patients af-
ter open surgery with cardiopulmonary bypass (CPB).1 The
development of postoperative renal dysfunction always is
associated with a high mortality and accompanied by
a higher incidence of gastrointestinal bleeding, respiratory
infections, and sepsis.2 Hypovolemia, ischemia–reperfu-
sion, inflammation, and nephrotoxic factors are involved
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The Journal of Thoracic and Cato kidney injury.3 Proteinuria or decline in the glomerular
filter rate often is observed after CPB, especially in patients
with hypertension, diabetes, or preexisting renal disease.
Erythropoietin is a hypoxia-induced hormone that is
essential for normal erythropoiesis. Recent studies have
shown that erythropoietin has broader actions in addition
to the stimulation of erythroid precursors.4-7 Recombinant
human erythropoietin (RhEPO) was reported to have a
protective effect on subsequent renal ischemia–reperfusion
injury,5 to enhance tubular epithelial regeneration, and to
promote renal functional recovery in hypoxic or ischemic
ARI.6 Because rhEPO can ameliorate ischemia–reperfusion
injury and the inflammatory response,4-7 which are 2 main
pathophysiologic process of ARI after CPB, it may provide
renal protection against CPB. However, research concerning
this is relatively limited.
Canonical transient receptor potential channel 6
(TRPC6) channel is a Ca2þ-selective channel that has
been identified as an essential interacting protein at the re-
nal podocyte slit diaphragm.8 It can directly interact with
the key structure and signaling proteins of podocyte,rdiovascular Surgery c Volume 146, Number 3 681
Abbreviations and Acronyms
ARI ¼ acute renal injury
CPB ¼ cardiopulmonary bypass
EMSA ¼ electrophoretic mobility shift assay
IP ¼ intraperitoneally
NFAT ¼ nuclear factor of activated T cell
NFATc1 ¼ nuclear factor of activated T-cells,
cytoplasmic, calcineurin-dependent 1
PBS ¼ phosphate-buffered saline
RhEPO ¼ recombinant human erythropoietin
TRPC6 ¼ canonical transient receptor potential
channel 6
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Mpodocin, and nephrin.8 Many studies have implicated that
TRPC6 has crucial roles in hereditary glomerular dysfunc-
tion and acquired glomerular diseases.9-12 Chu and
colleagues13 recently demonstrated modulation of calcium
influx through a certain subtype of TRPC channels by eryth-
ropoietin. Nuclear factor of activated T cell (NFAT) has
been described as one of the most important signals down-
stream of TRPC6 activation. The link between TRPC6 and
the calcineurin-NFAT pathway has been established in
some types of cells, including cardiac myocytes and renal
podocyte.14,15 NFAT activation was considered a key
intermediate step in the pathogenesis of mutant TRPC6-
mediated focal segmental glomerulosclerosis, and suppres-
sion of NFAT activity may contribute to the antiproteinuric
effects of calcineurin inhibitors.16 The present study (1) ex-
plores the dose-related renal protective effects of rhEPO
against glomerular injury after CPB in a rat in vivo model,
(2) determines the expression of glomerular TRPC6 after
CPB and regulation of this channel by rhEPO, and (3) eval-
uates NFATc1 activity after CPB and the effects of rhEPO
on this transcription factor.
MATERIALS AND METHODS
Animals and Drugs
Adult male Sprague Dawley rats (body weight, 400  50 g) were
purchased from the Animal Center of the Chinese Academy of Science,
Shanghai, and randomly divided into experimental groups. All proce-
dures were performed in accordance with The Guide for the Care
and Use of Laboratory Animals from the National Institutes of Health
(Publication No. 85-23, revised 1996). The rats were acclimated in
a quarantine room and maintained on a standard pellet diet at the An-
imal Center of Shanghai Jiaotong University for 10 days before surgery.
The following experimental protocol was approved by the Shanghai
Jiaotong University Animal Care and Use Committee. The rhEPO
was donated from Shenyang Sunshine Pharmaceutical Co, Ltd
(Shenyang, China).
Experimental Protocol
The study consisted of 2 phases. In phase 1, a dose-effect relationship
was studied and the most effective dosage was determined. Rats were ran-
domly assigned to 5 experimental groups: (1) sham group (S group,682 The Journal of Thoracic and Cardiovascular Surgn ¼ 6), (2) CPB group (C group, n ¼ 6), (3) rhEPO (500 U/kg, intraper-
itoneally [IP]) group (E1 group, n ¼ 6), (4) rhEPO (3000 U/kg, IP) group
(E2 group, n ¼ 6), and (5) rhEPO (5000 U/kg, IP) group (E3 group,
n ¼ 6). In phase II, another 3 groups were enrolled: (1) sham group
(S group, n ¼ 30), (2) CPB group (C group, n ¼ 30), and (3) rhEPO group
(the most effective dosage according to phase I, n ¼ 30). In the sham and
CPB groups, a 0.9% saline solution (4 mL/kg, IP) was given 24 hours be-
fore the operation protocol. In all rhEPO groups, different doses of rhEPO
were diluted in 4 mL/kg saline solution and injected IP 24 hours before the
surgery protocol.
Surgical Procedure
The rat model of CPB was built according to Zhu and colleagues.17
Rats were anesthetized with IP administration of pentobarbital
(50 mg/kg) at the beginning. Additional pentobarbital was added to en-
sure an adequate depth of anesthesia during surgery. The right femoral
artery was cannulated with a 24-gauge polytetrafluoroethylene catheter
to monitor arterial pressure and collect blood samples. After administra-
tion of heparin (250 U/kg), a 16-gauge catheter, modified to a multiside-
orifices cannula in the forepart, was inserted into the right jugular vein
and advanced to the right atrium. A 22-gauge catheter was cannulated
to the tail artery to serve as the arterial infusion line. The mini-CPB cir-
cuit comprised a venous reservoir, a specially designed membrane oxy-
genator, a roller pump, and sterile polyvinyl chloride tubing with an
internal diameter of 3 mm for the venous and arterial lines (30 cm
long). The roller pump was equipped with a silicone tube 15 cm in length
with an internal diameter of 5 mm. The membrane oxygenator was spe-
cially designed with a surface area for gas exchange of 0.05 m2 (Micro-1;
Kewei Medical Instrument Inc, Dongguan, China), with its total assembly
dynamic priming volume approximating 2 mL. Body central temperature
was monitored with a rectal probe and kept at 36.5C to 38.0C by a heat
lamp placed around the animal and the CPB equipment. We primed the
CPB circuit with 12 mL of a solution of heparin (250 U/kg) and hetas-
tarch. Before the initiation of extracorporeal circulation, the CPB set
was examined carefully to avoid liquid and air leaks. The blood was
drained from the right atrium through the jugular vein catheter to
a 5-mL sterile open reservoir by gravity and siphon. A roller pump
(BT00-300M; Lange Co, Baoding, China) was used to drive the blood
through silicone arterial inflow tubing and then return it to the tail artery.
At the initiation of perfusion, the flow rate was gradually increased to 100
mL/(kg $ min) and maintained for 60 minutes; it was then turned down
step by step to maintain hemodynamic stability. When the rat was weaned
from CPB, the tail artery catheter was removed, and the right jugular vein
catheter was drawn back to the superior vena cava. The remaining prim-
ing solution was infused gradually when the main arterial pressure was
less than 60 mm Hg. After 1 hour of intensive postoperative care, the
right jugular vein catheter and the femoral artery catheter were decannu-
lated. Then, the neck, tail, and groin incisions were sutured. Throughout
the experiment, the mean arterial pressure was maintained at approxi-
mately 60 to 80 mm Hg. The rats were given water and food 6 hours after
the operation, and they were monitored for 24 postoperative hours.
Phase I: Specimen Collection
Mean arterial pressures were recorded during the experiment. Blood
samples (1 mL) were obtained from the femoral artery immediately after
heparinization and at 2, 4, 24, 48, and 72 hours after operation for serum
creatinine and cystatin-C measurements. The urine also was collected for
protein content determination at these time points.
Biochemical Index Measurement
Serum creatinine and cystatin C were quantified by enzyme-linked im-
munosorbent assays (WinhongBio, Shanghai, China) according to theman-
ufacturer’s instruction. Serum creatinine and cystatin C values were
expressed as micromoles/liter and micrograms/liter separately. Urineery c September 2013
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Mprotein was assayed on a chemistry analyzer (model 7600-020; Hitachi,
Ltd, Tokyo, Japan) and expressed as grams/liter.
Phase II
At 4, 24, 48, and 72 hours after the operation, the kidneys were
harvested for subsequent separate assessment (n ¼ 6 for each time point
in every group).
Electron Microscopic Observation of Filtration
Barrier and Podocyte
One cubic millimeter of fresh kidney tissue, cut from the cortical
nephron, was prefixed with 2.5% glutaraldehyde and post-fixed with 1%
osmium tetroxide. The specimens were immersed in propylene oxide after
dehydration with gradient ethanol, embedded with epoxy resin, and made
into ultrathin sections. The sections were stained subsequently with
lead-uranium, and the changes of ultra-structural organization were then
evaluated by a transmission electron microscope (JEM-1200EX; JEOL
Ltd, Tokyo, Japan).
Isolation of Glomeruli
The kidneys were removed from adult Sprague Dawley rats, and the cor-
tex and medulla were isolated by dissection. Cortex, minced into 1 mm3
pieces, was gently pressed through a 106-mm cell strainer using a flattened
pestle. The filtrate was passed through a new 100-mm cell strainer. The fil-
trate was collected and passed through a 70-mm cell strainer. Glomeruli,
which accumulated on the 70-mm strainer, were washed with 5 mL of
Hank’s Balanced Salt Solution and collected. The glomerular suspension,
which by microscopic inspection was approximately 90% glomeruli,
was subjected to centrifugation at 200g for 5 minutes. The supernatant
was discarded, and the glomerular pellet was resuspended in lysis buffer.
Immunofluorescence
Frozen sections (6 mm) from adult rat kidneys were fixed in paraformal-
dehyde for 30 minutes. The sections were briefly rinsed in phosphate-
buffered saline (PBS) and subsequently incubated with blocking solution
containing 3% immunoglobulin-G–free body surface area (Vector Labora-
tories Inc, Burlingame, Calif), 10% normal donkey serum (Jackson Immu-
noResearch, West Grove, Pa), and 0.1% Triton X-100 (Jackson
ImmunoResearch) for 1 hour at room temperature. Sections were incubated
with TRPC6 polyclonal antibody (1:100; Abcam, Cambridge, UK), and nu-
clei were counterstained with 40-6-diamidino-2-phenylindole (Beyotime;
Haimen, Jiangsu Province, China) overnight at 4C. After the sections
were washed 3 times for 5 minutes with PBS at room temperature, they
were incubated with Alexa 488-conjugated anti-rabbit antibody (1:200;
Life Technologies, Frederick,Md) for 1 hour at room temperature. Sections
were washed 3 times with PBS for 5 minutes and mounted with antifade
mountingmedium (Beyotime). Images were acquired using a Leica upright
fluorescence microscope (Leica DM2500; Leica, Wetzlar, Germany)
equipped with a computer-controlled mechanical stage and a SPOT RT
camera. Total magnification is given in Figures 1 and 2.Western Blot Assay
After quantification of the protein samples using the BCA Protein Assay
Kit (Pierce Biotechonology, Rockford, Ill), we electrophoresed 30 mg of total
protein through a 10% sodium dodecyl sulfate-polyacrylamide gel and then
wet electro-transferred to 0.45-mm nitrocellulose membranes (Whatman;
Dassel, Germany). The blots were incubated overnight at 4C with anti-
TRPC6 antibody (1:100; Abcam) and incubated with a goat anti-rabbit
polyclonal horseradish peroxidase–conjugated secondary antibody (1:5000,
Jackson ImmunoResearch). Protein signals were detected using an enhanced
chemiluminescence detection system (Pierce Biotechonology). An anti–
b-actin antibody with 1:1000 dilution (Santa Cruz Biotechnology,The Journal of Thoracic and CaSanta Cruz, Calif) was used to normalize sample loading and transfer. The
intensities of the bands were quantified by densitometry using Gel-Pro Ana-
lyzer (Media Cybernetics, Rockville, Md). Figure 3 shows representative re-
sults from experiments repeated 6 times.
Extraction of Nucleoprotein
Extraction of glomerular nucleoprotein was performed using the
NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce Biotechnol-
ogy) according to the manufacturer’s instruction. Nucleic protein con-
centration was determined using a BCA Protein Assay Kit (Pierce
Biotechnology).
Nuclei NFATc1 Activity Assay
Nuclei NFATc1 activities were analyzed by TransAM NFATc1 Tran-
scription Factor Assay Kit (Active Motif, Carlsbad, Calif), according to
the manufacturer’s instruction, and electrophoretic mobility shift assay
(EMSA). EMSA was performed using a commercial kit (Gel Shift Assay
System; Promega, Madison, Wis). Double-stranded oligonucleotides (50-
CGCCCAAAGAGGAAAATTTGTTTCATA-30, 30-GCGGGTTTCTCCT
TTTAAACAAAGTAT-50 for NFATc1) were labeled with [g-32P]ATP us-
ing the T4 polynucleotide kinase. Nuclear protein (10mg)was preincubated
in a total volume of 20 mL consisting of 20 mmol/L HEPES-KOH (pH 7.8),
75mmol/LKCl, 2.5mmol/LMgCl2, 1mmol/L ethylenediaminetetraacetic
acid, 1 mmol/L phenylmethylsulfonylfluoride, 1 mmol/L dithiothreitol,
4.5 mg bovine serum albumin, 2 mg poly(dI-dC), 10% glycerol, and
100,000 cpm [g-32P]ATP labeled double-stranded NFAT-binding oligonu-
cleotide probe for 30 minutes on ice. After addition of the 32P-labled oligo-
nucleotide probe, the incubation was continued for 20 minutes at room
temperature. Reaction was stopped by adding 1 mL of gel loading buffer,
and the mixture was subjected to nondenaturing 6% polyacrylamide gel
electrophoresis in 0.53Tris-borate-ethylenediaminetetraacetic acid buffer.
After electrophoresis was conducted at 100Vat 4C for 2 hours, the gel was
vacuum-dried and exposed to x-ray film (Fuji Hyperfilm, Tokyo, Japan) at
70C with an intensifying screed.
Statistics
Statistical analyseswere performedwith SPSS 10.0 (SPSS Inc, Chicago,
Ill). Comparisons of urine protein, serum injury markers among the
5 groups, and intensity of Western blot bands and nuclei NFATc1 activities
were performed using repeated-measures 1-way analysis followed by
Student–Newman–Keuls post hoc test. All data are presented as
mean  standard deviation.RESULTS
Phase I: Effects of RhEPO on Postoperative Urine
Protein and Serum Glomerular Injury Markers
Postoperative urine protein contents, serum creatinine,
and cystatin-C at all time points are listed in Table 1. Com-
pared with the S group, urine protein levels remarkably
increased after surgery. The elevation of postoperative urine
protein was significantly inhibited in the E2 group (P<.05)
and E3 group (P<.01) compared with the C group. There
were no significant differences between the E2 and E3
groups (P¼ .1). Serum creatinine and cystatin-Cwere stable
in the S group throughout the experiment. Serum creatinine
started to increase at 24 hours after surgery and was signif-
icantly higher than the baseline in the other 4 CPB groups.
RhEPO significantly reduced the serum creatinine increase
in the E2 group (P<.01) and E3 group (P<.01). Serumrdiovascular Surgery c Volume 146, Number 3 683
TABLE 1. Postoperative urine protein contents, serum creatinine, and cystatin-C at every time point
Group Baseline 2 h 4 h 24 h 48 h 72 h
Urine protein (g/L)
S group 2.25  1.10 2.18  1.07 2.30  0.93 2.60  1.09 2.37  1.18 2.40  0.92
C group 2.23  1.15 4.60  1.92* 13.07  1.87y 11.83  1.72y 7.47  1.02y 11.28  1.73y
E1 group 2.32  1.18 3.98  0.90* 12.42  1.32y 10.43  1.22y 7.83  0.67y 10.28  1.14y
E2 group 2.28  1.18 4.10  0.84* 10.32  1.93y,x 8.77  1.32y,x 7.78  1.02y 8.97  0.89y,x
E3 group 2.37  1.16 2.99  1.50z 9.38  1.03y,x 8.73  1.55y,x 6.57  1.13y 7.82  1.13y,x
Serum creatinine (mmol/L)
S group 20.50  2.3 21.50  2.8 21.33  4.9 19.50  1.8 20.50  3.3 20.17  1.5
C group 22.36  3.5 23.17  4.6 22.33  4.9 71.00  7.7y 66.00  10.2y 60.67  7.6y
E1 group 20.5  2.0 20.50  1.9 20.50  1.6 68.17  7.6y 59.33  7.1y 54.50  5.2y,x
E2 group 22.33  1.8 21.17  2.3 20.33  2.2 42.00  3.6y,x 40.00  3.2y,x 37.67  1.6y,x
E3 group 21.17  1.5 22.33  1.5 21.17  1.5 38.17  4.2y,x 38.33  3.1y,x 35.00  3.5y,x
Serum cystatin-C (mg/L)
S group 283.7  24.5 282.8  20.7 284.9  22.6 279.8  16.6 276.9  23.7 287.6  23.1
C group 278.2  21.4 452.6  63.8y 373.3  16.3y 356.1  22.9y 282.9  24 340.5  45.1y
E1 group 273.9  17.2 456.7  65.0y 370.9  31.1y 383.5  18.2y,z 281.9  24.7 318.8  13.1
E2 group 277.9  18.6 429.2  45.7y 369.6  34.8y 371.4  12.8y 293.1  13.8 312.9  25.5
E3 group 280.2  26.9 336.5  28.2x 350.7  33.1y 282.9  17.2x 290.8  27.7 331.4  29.7y
*P<.05. yP<.01 versus S group at the same time point. zP<.05. xP<.01 versus C group at the same time point.
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Mcystatin-C began to increase early after surgery. Only
5000 U/kg rhEPO in the E3 group remarkably inhibited
the serum cystatin-C increase (P< .001) compared with
the C group.
Phase II: Effects of RhEPO on Podocyte
Ultrastructure
Representative electron microscopic pictures are pre-
sented in Figure 1. Normal foot process and slit diaphragms
were observed in the S group. In the C group, foot processes
were effaced and ran together. Irregular adhesion and even
fusion between foot processes appeared. In the E group,
foot processes also formed irregular adhesion and were api-
cally mislocalized. However, the morphologic abnormali-
ties were improved.
Effects of RhEPO on Glomerular TRPC6 Activity:
Immunofluorescence and Immunoblots
Immunofluorescence analysis revealed that TRPC6 chan-
nel was present in normal glomeruli in the S groupwith a rel-
atively low activity. This is consistent with recent studies that
demonstrated that TRPC6 was expressed in podocyte inFIGURE 1. Representative electron microscopic pictures for podocyte
foot process ultrastructure (360,000).
684 The Journal of Thoracic and Cardiovascular Surgglomeruli. CPB induced a remarkable increase in glomerular
TRPC6 at 24, 48, and 72 hours postoperatively. Bolus injec-
tion of 5000 U/kg rhEPOmarkedly attenuated CPB-induced
increases in the signals of glomerular TRPC6. Representa-
tive immunofluorescence pictures of 3 groups at 72 hours
after surgery are shown in Figure 2. To quantify the effects
of rhEPO on the CPB-induced changes of glomerular
TRPC6, we conductedWestern blot assays using TRPC6 an-
tibody, showing that CPB induced a significant increase in
glomerular TRPC6 signals for 24 hours after surgery. Fur-
thermore, this increase remained significant at 72 hours post-
operatively, which was attenuated by administration of 5000
U/kg rhEPO (Figure 3, A). Quantifications of the Western
blot results indicate that 5000 U/kg rhEPO significantly
attenuated CPB-induced increases in the levels of glomeru-
lar TRPC6 (Figure 3, B, P<.01 vs group C).Effects of RhEPO on Glomerular Nuclei NFATc1
Activity
Nuclei NFATc1 activities in the S group were stable and
relatively low during the whole experiment. There was no
statistical difference among the 3 groups at baseline. After
surgery, glomerular nuclei NFATc1 production was remark-
ably activated from 4 to 72 hours postoperatively. Both
enzyme-linked immunosorbent assay kit (Figure 4, A) and
quantifications of the EMSA assay revealed that 5000 U/kg
rhEPO significantly attenuated CPB-induced nuclei NFATc1
activation (Figure 4,B andC). Representative EMSApictures
indicating NFATc1 binding activity in the C and E groups at
every time point are shown inFigure 4,B. Quantitative data of
nuclei NFATc1 obtained at different time points are shown in
Figure 4, C.ery c September 2013
FIGURE 2. Representative glomerular TRPC6 immunofluorescence
pictures of 3 groups at 72 hours after surgery (3200). TRPC6, Canonical
transient receptor potential channel 6; DAPI, 40,6-diamidino-2-
phenylindole.
FIGURE 4. A-C, Nuclei NFATc1 activities of 3 groups after surgery.
NFATc1, Nuclear factor of activated T-cells, cytoplasmic, calcineurin-
Liu et al Perioperative ManagementDISCUSSION
Our results showed that rhEPO dose-dependently pre-
vented CPB-induced acute renal glomerular injury. A
higher dose revealed better effects. Glomerular TRPC6
expression and nuclear translocation of NFATc1 were
greatly enhanced after CPB. Pretreatment with 5000 U/kg
rhEPO significantly suppressed the TRPC6-NFATc1 path-
way activation.
By considering the functional significance in physiologic
situation and susceptibility to pathologic stress, our study
for the first time evaluated the dose-related glomerularFIGURE 3. Western blot assay for glomerular TRPC6 after surgery
(A) and quantification results (B). TRPC6, Transient receptor potential
canonical 6. *P < .05, **P < .01 versus S group at the same time.
#P<.05, ##P<.01 versus C group at the same time.
dependent 1. *P < .05, **P < .01 versus S group at the same time.
#P<.05, ##P<.01 versus C group at the same time.
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Mprotective effects of rhEPO using an in vivo rat CPB model.
Serum creatinine has been the most widely used glomerular
marker in the last 50 years, although with well-known lim-
itations. Cystatin-C is a plasmatic protein of low molecular
weight, which is filtrated through the basal membrane of
the glomeruli and almost immediately reabsorbed and de-
graded by the proximal tubules, because the glomerular fil-
tration is its only elimination outlet.18 For this reason,
serum cystatin-C has been considered one of the most reli-
able markers of glomerular function in extensive experi-
mental and clinical research, including cardiac surgery.19
Therefore, in phase I of the present study, both serum cre-
atinine and cystatin-C together with urine protein content
during 72 hours postoperatively were assayed to determine
the glomerular protective effects of 3 doses of rhEPO. Our
study showed that 5000 U/kg rhEPO exerted a potent glo-
merular protective effect against CPB, demonstrated byrdiovascular Surgery c Volume 146, Number 3 685
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Ma reduction of serum creatinine, cystatin-C, and urine
protein.
The renal glomerulus operates as a sieve that is permeable
towater and small soluteswhile largely excludingmacromol-
ecules on the basis of size and charge by retaining them in
the blood. Podocytes are cells in the glomeruli that line the
filtering capillaries and constitute amajor part of the filtration
apparatus by providing foot processes with interconnected
slit diaphragms, which form a seal to macromolecules.20 It
has been clear that proteinuria is almost inevitably associated
with podocyte injury.21According to our results, the injury of
the glomerulus filtration barrier manifested by fusion and
effacement of podocyte foot processes suggests the dysfunc-
tion of renal filtration in an ultrastructural manner, which
was also improved by 5000 U/kg rhEPO.
The TRPC6 channel is one of the critical components of
slit diaphragms. It is enriched in the podocyte foot processes
in glomeruli. It has beenwidely demonstrated to play critical
roles in glomerular filtration and podocyte signaling by
providing scaffold and mechanosensitive properties to the
filtration site.8 Reiser and colleagues9 discovered that disrup-
tion of the slit diaphragm architecture in nephrin-deficient
mice led to overexpression and mislocalization of TRPC6
in podocytes and suggested that TRPC6 is a glomerular slit
diaphragm–associated channel required for normal renal
function. In addition to the evidence that gain-of-function
mutations in the TRPC6 gene are causes in the familial
form of focal segmental glomerulosclerosis,11,22 elevated
levels ofwild-typeTRPC6protein in acquired glomerulardis-
eases can lead to podocyte dysfunction.12 Therefore, in phase
II of the present study, we aimed to explore whether the
glomerular protective effect of rhEPO against CPBwas asso-
ciatedwith regulation of glomerular TRPC6 expression. Both
immunofluorescence and immunoblots were performed to
detect TRPC6 activity. Our results revealed that CPB induced
a significant increase in glomerular TRPC6 signals from
24 to 72 hours after surgery, which could be remarkably
attenuated by administration of 5000 U/kg rhEPO.
Several signaling events have been described down-
stream of TRPC6 activation, one of which is activation of
calcium-dependent NFAT transcription factor. Overexpres-
sion of TRPC6 in cardiac myocytes in vitro and in vivo
could lead to activation of the calcineurin-NFAT pathway
and cardiac hypertrophy in response to angiotensin II.14
NFATc1 (also called ‘‘NFAT2’’) is one of the NFAT family
members. On activation by increased intracellular Ca2þ, cal-
cineurin dephosphorylates the NFATc1 proteins, which
leads to the translocation from cytoplasm to nucleus of
this protein. Recent studies suggested that NFAT activation
may be a key intermediate step in the pathogenesis ofmutant
TRPC6-mediated focal segmental glomerulosclerosis15,16
and that suppression of NFAT activity may contribute to
the antiproteinuric effects of calcineurin inhibitors.15,23
According to our results, increased glomerular TRPC6686 The Journal of Thoracic and Cardiovascular Surgexpression after CPB was accompanied by activated nuclei
NFATc1 from 24 to 72 hours postoperatively, which meant
that the upregulation of glomerular TRPC6 by CPB was
transcriptive and functional. However, pretreatment of
5000 U/kg rhEPO significantly attenuated the activation of
TRPC6 and nuclei NFATc1. Therefore, the renal protection
of rhEPO pretreatment against CPB may be partly due to
downregulation of glomerular TRPC6-NFATc1 pathway.
Study Limitations
First, a preliminary study was not performed to evaluate
the sample size. We conventionally assigned 6 animals to
each group and found 5000 U/kg to be the most effective
dose. Perhaps a lower dose could provide a comparable ef-
fect if a larger sample size was applied. Second, our results
were achieved in small rodents. Whether such an inspiring
result also could be acquired in large animals or humans is
still unclear, and further investigations are needed. Third, in
clinical practice, we care more about the patients with ab-
normal preoperative renal function, such as those with a his-
tory of hypertension or diabetes. The results of normal
preoperative renal function may not totally translate in
those special patients. However, many studies have reported
the renal protection of rhEPO against endotoxemia, ische-
mia–reperfusion, and antineoplastic agent–induced nephro-
toxity.5,6,24,25 Our results and these findings may suggest
a new approach for perioperative management in the future.
CONCLUSIONS
The present study demonstrated that 5000 U/kg of rhEPO
prevented CPB-induced acute renal glomerular injury and
that CPB significantly enhanced glomerular TRPC6 expres-
sion and nuclear NFATc1 activation, whichmight contribute
to the abnormality of the podocyte foot process and injury of
the infiltration membrane. In addition, 5000 U/kg rhEPO
suppressed TRPC6 overexpression and nuclei NFATc1 acti-
vation induced by CPB. Therefore, the protection of rhEPO
pretreatment against CPBmay be partly due to downregula-
tion of the glomerular TRPC6-NFATc1 pathway.
The authors thank Ximing Chen, PhD, and Rufeng Jin, MD, for
statistical analysis.
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